United Therapeutics (UTHR) has a history of beating earnings estimates, with positive predictions for the next report.

United Therapeutics (UTHR) is a stock with a history of beating earnings estimates in the medical industry. Recent reports show an average surprise of 10.41%, with last quarter’s earnings at $6.17 per share vs. $5.63 expected. Analysts predict a positive surprise for the next quarterly report, making this stock a strong contender.

With a positive Earnings ESP of +4.91% and a Zacks Rank #3 (Hold), United Therapeutics is poised for another earnings beat. The Earnings ESP compares analyst estimates for the quarter, showing bullish sentiment for the company’s earnings prospects. This combination of factors indicates a high likelihood of exceeding expectations in the upcoming report.

Investors should note that a negative Earnings ESP reduces predictive power but does not guarantee an earnings miss. While beating EPS estimates can lead to share price gains, other factors also influence stock performance. Checking a company’s Earnings ESP before its quarterly release can increase success odds. Utilize tools like the Earnings ESP Filter to make informed investment decisions.

Zacks experts have identified a little-known chemical company as a top stock pick with potential to double in value. With strong demand, rising earnings estimates, and shares available for repurchase, this company presents an opportunity for retail investors. Previous Zacks picks have seen significant growth, making this stock an exciting prospect for investors.

Read more at Nasdaq: Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?